Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial

Charlotte Pawlyn, MD, Faith E. Davies, MD, Walter M Gregory, PhD, Alex J Szubert, MSc, Sue E Bell, DPhil, Jacqueline Ouzman, PhD, Mark T Drayson, MD, Roger G Owen, MD, Graham H Jackson, MD, Nigel H Russell, MD, Gareth J. Morgan, MD, PhD

Blood (2012) 120 (21): 335.

https://doi.org/10.1182/blood.V120.21.335.335

Published: 2012

Journal Articles

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Alex J. Szubert, Sue E. Bell, Mark T. Drayson, Roger G. Owen, A. John Ashcroft, Graham H. Jackson, J. Anthony Child

Blood (2012) 119 (23): 5374–5383.

https://doi.org/10.1182/blood-2011-11-392522

Published: 2012

Includes: Supplemental data

Journal Articles

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

Gareth J Morgan, MD PhD, Faith E Davies, MD, Walter M Gregory, PhD, Sue E Bell, DPhil, Alex J Szubert, MSc, Gordon Cook, Mark T Drayson, MD, Roger G Owen, MD, Fiona M Ross, DPhil, Graham H Jackson, MD, J. Anthony Child, MD

Blood (2011) 118 (21): 993.

https://doi.org/10.1182/blood.V118.21.993.993

Published: 2011

Journal Articles

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Kevin D Boyd, MD, Fiona M Ross, DPhil, Mark T Drayson, MD, Roger G Owen, MD, Alex J Szubert, MSc, Walter M Gregory, PhD, Christopher P Wardell, PhD, Faith E Davies, MD, Graham H Jackson, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD PhD

Blood (2011) 118 (21): 1823.

https://doi.org/10.1182/blood.V118.21.1823.1823

Published: 2011

Journal Articles

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M. Gregory, PhD, Sue E. Bell, PhD, Alex J. Szubert, MSc, Nuria Navarro-Coy, MPhil, Mark T. Drayson, MD, PhD, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, PhD, Graham H. Jackson, MD, J. Anthony Child, MD

Blood (2010) 116 (21): 623.

https://doi.org/10.1182/blood.V116.21.623.623

Published: 2010

Journal Articles

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Gareth J Morgan, MD, PhD, Faith E Davies, MD, Walter M Gregory, Susan E Bell, Alex J Szubert, Kim Cocks, Nuria Navarro Coy, Mark T Drayson, Roger G Owen, Fiona M Ross, DPhil, Graham H Jackson, J. Anthony Child

Blood (2009) 114 (22): 352.

https://doi.org/10.1182/blood.V114.22.352.352

Published: 2009

Journal Articles

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations.

David C Johnson, BSc, Walter M Gregory, PhD, Nicholas J Dickens, DPhil, Brian A Walker, PhD, Alex J Szubert, MSc, Faith E Davies, MD, Brian G M Durie, MD, Brian G Van Ness, PhD, Gareth J Morgan, MD, PhD

Blood (2009) 114 (22): 426.

https://doi.org/10.1182/blood.V114.22.426.426

Published: 2009

Journal Articles

Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients.

David C Johnson, Christine Ramos, Alex J. Szubert, Walter M Gregory, J. Anthony Child, Faith E Davies, MD, Brian GM Durie, MD, Brian G. Van Ness, PhD, Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 1675.

https://doi.org/10.1182/blood.V112.11.1675.1675

Published: 2008

Journal Articles

Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation

Gareth J Morgan, MD, PhD, Graham H Jackson, Faith E Davies, MD, Mark T Drayson, Roger G Owen, Walter M Gregory, Dena C Cohen, Alex J. Szubert, Susan E Bell, Fiona Ross, James A Child

Blood (2008) 112 (11): 656.

https://doi.org/10.1182/blood.V112.11.656.656

Published: 2008

NARROW

Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations.

Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients.

Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only